|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||||||||||
  Clinical & Experimental OphthalmologyVolume 34 Issue 4, Pages 365 - 374 Published Online: 8 Jun 2006 Journal Compilation © 2009 Royal Australian and New Zealand College of Ophthalmologists Published on behalf of the Royal Australian and New Zealand College of Ophthalmologists
Abstract | References | Full Text: HTML, PDF (Size: 105K) | Related Articles | Citation Tracking  Perspective Biologic therapies for inflammatory eye disease Copyright 2006 Royal Australian and New Zealand College of Ophthalmologists KEYWORDS biologic • immunosuppression • uveitis Abstract
The era of biologic medical therapies provides new options for patients with treatment-resistant inflammatory eye disease. In this review, the authors summarize current published experience in a rapidly progressing clinical field, including the use of biologics, such as the tumour necrosis factor blockers, daclizumab and rituximab, and related agents, interferons and intravenous immunoglobulin, for the treatment of uveitis, scleritis and orbital inflammation. Reports of dramatic recoveries in patients with recalcitrant ocular inflammation who have received such therapies must be balanced against the high cost of biologics and the potential for serious, and at times unanticipated, complications of this treatment. Received 13 November 2005; accepted 10 February 2006. | 
|
